Literature DB >> 15966242

Prognostic and clinical evaluation of patients with T2 gastric cancer.

Shuhei Komatsu1, Daisuke Ichikawa, Hideaki Kurioka, Keitaro Kan, Yasuhiro Shioaki, Yasuo Ueshima, Takashi Hamashima, Chol Joo Lee, Eito Ikeda, Yuji Ueda, Eigo Otsuji, Takahiro Oka, Hisakuso Yamagishi.   

Abstract

BACKGROUND/AIMS: Little is known about the clinicopathological features of intermediate-stage T2 gastric cancer, defined as tumors invading the muscularis propria or subserosa.
METHODOLOGY: Of 808 patients with gastric cancer, 210 patients (25.9%) who underwent gastrectomy for T2 gastric cancer were selected for this retrospective study. The clinicopathologic findings of these patients were analyzed retrospectively from their hospital records.
RESULTS: Of all 808 patients with gastric cancer, 73 patients (9.0%) had tumors invading the muscularis propria (mp). The remaining 137 patients (16.9%) had tumors invading the subserosa (ss). Compared with ss gastric cancer, mp gastric cancer was associated with smaller tumor size, an absence of lymphatic spreading, and hematogenous and late recurrence [disease-free interval: 654.5 days (mp) vs. 365.5 days (ss)]. Univariate analysis of cases with curative operations showed that lymphatic invasion, and lymph node metastasis were significant prognostic factors in patients with T2 gastric cancer. Further examination by multivariate analysis demonstrated that pN2 or higher as classified by both the JCGC (Japanese Classification of Gastric Cancer) and the TNM lymph node staging systems was a predictor of poor prognosis.
CONCLUSIONS: JCGC and TNM lymph node staging systems were the most reliable prognostic factors for T2 gastric cancer. Close follow-up should be required for patients with stage pN2 or higher gastric cancer. Long-term follow-up should be required for mp cancers, in particular.

Entities:  

Mesh:

Year:  2005        PMID: 15966242

Source DB:  PubMed          Journal:  Hepatogastroenterology        ISSN: 0172-6390


  6 in total

1.  Defining a high-risk subgroup of pathological T2N0 gastric cancer by prognostic risk stratification for adjuvant therapy.

Authors:  Chunyan Du; Ye Zhou; Kai Huang; Guangfa Zhao; Hong Fu; Yingqiang Shi
Journal:  J Gastrointest Surg       Date:  2011-09-22       Impact factor: 3.452

2.  Is subdivision of pT2 tumors superior to lymph node metastasis for predicting survival of patients with gastric cancer? Review of 224 patients from four centers.

Authors:  Ahmet Bilici; Faysal Dane; Mesut Seker; Bala Basak Oven Ustaalioglu; Mehmet Aliustaoglu; Suleyman Temiz; Cem Gezen; Dilek Yavuzer; Gorkem Aksu; Alpaslan Mayadagli; Mahmut Gumus; Kazim Uygun; Nazim Serdar Turhal
Journal:  Dig Dis Sci       Date:  2011-06-10       Impact factor: 3.199

3.  Preoperative diagnosis of lymph node metastases in gastric cancer by magnetic resonance imaging with ferumoxtran-10.

Authors:  Yoshiaki Tatsumi; Nobuhiko Tanigawa; Haruto Nishimura; Eiji Nomura; Hideaki Mabuchi; Mitsuru Matsuki; Isamu Narabayashi
Journal:  Gastric Cancer       Date:  2006       Impact factor: 7.370

4.  Risk factors for selection of patients at high risk of recurrence or death after complete surgical resection in stage I gastric cancer.

Authors:  Ji Hyun Park; Min-Hee Ryu; Hwa Jung Kim; Baek-Yeol Ryoo; Changhoon Yoo; Inkeun Park; Young Soo Park; Sung Tae Oh; Jeong Hwan Yook; Byung Sik Kim; Yoon-Koo Kang
Journal:  Gastric Cancer       Date:  2015-01-23       Impact factor: 7.370

5.  Satisfactory surgical outcome of T2 gastric cancer after modified D2 lymphadenectomy.

Authors:  Shupeng Zhang; Liangliang Wu; Xiaona Wang; Xuewei Ding; Han Liang
Journal:  Chin J Cancer Res       Date:  2017-04       Impact factor: 5.087

6.  Clinical impact of postoperative interval until adjuvant chemotherapy following curative gastrectomy for advanced gastric cancer.

Authors:  Yusuke Takashima; Shuhei Komatsu; Keiji Nishibeppu; Jun Kiuchi; Takuma Ohashi; Hiroki Shimizu; Tomohiro Arita; Yusuke Yamamoto; Hirotaka Konishi; Ryo Morimura; Atsushi Shiozaki; Yoshiaki Kuriu; Hisashi Ikoma; Takeshi Kubota; Hitoshi Fujiwara; Kazuma Okamoto; Eigo Otsuji
Journal:  J Cancer       Date:  2021-08-13       Impact factor: 4.207

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.